Tech Center 1600 • Art Units: 1648 1671 1672
This examiner grants 73% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18277186 | METHODS AND RELATED ASPECTS FOR DETECTING DISEASES, CONDITIONS, OR DISORDERS IN SUBJECTS USING EXTRACELLUAR VESICLES | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 18275540 | CATALYTIC AMPLIFICATION BY TRANSITION-STATE MOLECULAR SWITCHES FOR DIRECT AND SENSITIVE DETECTION OF SARS-COV-2 | Non-Final OA | National University of Singapore |
| 18282390 | METHODS FOR DETERMINATION OF TRANSPLANT REJECTION | Non-Final OA | Natera, Inc. |
| 18338128 | SEQUENCING MICROBIAL CELL-FREE NUCLEIC ACIDS TO DETECT INFLAMMATION, SECONDARY INFECTION, AND DISEASE SEVERITY | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18480009 | USE AND DETECTION METHOD OF FLAVIVIRUS PROTEIN MICROARRAY | Non-Final OA | NATIONAL CHENG KUNG UNIVERSITY |
| 18026943 | PIV5-BASED COVID-19 VACCINE | Final Rejection | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. |
| 18474895 | HBV DIAGNOSTIC, PROGNOSTIC, AND THERAPEUTIC METHODS AND PRODUCTS | Non-Final OA | Abbott Laboratories |
| 18506002 | TRANSGLUTAMINASE SUBSTRATES FOR LABELING | Non-Final OA | Roche Diagnostics Operations, Inc. |
| 18247565 | Cell culture process for producing RSV F protein | Non-Final OA | Pfizer Inc. |
| 18473064 | ORTHOPOXVIRUS SEROLOGY ASSAYS | Non-Final OA | Meso Scale Technologies, LLC. |
| 18350071 | Multiplex Assay for Simultaneous Detection of Equine Group A and B Rotaviruses and Genotyping of Equine Rotavirus A G3 And G14 | Non-Final OA | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College |
| 18251739 | METHODS AND COMPOSITIONS USING NON-INVASIVE PLASMA GLYCOMIC AND METABOLIC BIOMARKERS OF POST-TREATMENT CONTROL OF HIV | Non-Final OA | The Wistar Institute of Anatomy and Biology |
| 18286705 | EPSTEIN-BARR VIRUS MRNA VACCINES | Non-Final OA | ModernaTX, Inc. |
| 18282097 | THERAPEUTIC USE OF SARS-COV-2 MRNA DOMAIN VACCINES | Non-Final OA | ModernaTX, Inc. |
| 17576974 | LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) ON A SOLID-PHASE MEDIUM | Non-Final OA | Raytheon BBN Technologies, Corp. |
| 18267241 | IMMUNOGENIC PEPTIDE | Non-Final OA | UCL BUSINESS LTD. |
| 18282385 | FOLLICULAR HELPER T (TFH) CELLS SPECIFIC TO SARS-COV-2 VIRUS | Non-Final OA | KOTAI Biotechnologies, Inc. |
| 17995158 | Stabilized Vaccine Compositions | Non-Final OA | Janssen Vaccines & Prevention B.V. |
| 18213136 | COVID MULTI-BIOME | Non-Final OA | Microbiota I - Center (Magic) Limited |
| 18258562 | METHOD FOR DETERMINING ACTIVE SARS-COV-2-INFECTIONS | Non-Final OA | CEINGE BIOTECNOLOGIE AVANZATE FRANCO SALVATORE S.C. A R.L. |
| 18113193 | COMPOSITIONS AND METHODS FOR STABILIZING FLAVIVIRUSES WITH IMPROVED FORMULATIONS | Non-Final OA | TAKEDA VACCINES, INC. |
| 18002231 | NOVEL IMMUNE ADJUVANT AND VACCINE COMPOSITION INCLUDING THE SAME | Non-Final OA | REPUBLIC OF KOREA (ANIMAL AND PLANT QUARANTINE AGENCY) |
| 17991525 | COMPOSITIONS AND DEVICES FOR VACCINE RELEASE AND USES THEREOF | Non-Final OA | VAXESS TECHNOLOGIES, INC. |
| 17920625 | Suprastructure Comprising Modified Influenza Hemagglutinin With Reduced Interaction With Sialic Acid | Non-Final OA | Brian J. Ward |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy